Bristol-Myers' Opdivo snags FDA priority review for bigger lung cancer use

Bristol-Myers Squibb ($BMY) said the FDA fast-tracked its application for another indication for its PD-1 drug Opdivo, this time in patients with previously treated non-squamous non-small cell lung cancer. The immuno-oncology treatment first won approval to treat melanoma, but quickly racked up an indication in squamous NSCLC early this year. The BMS drug is racing with Merck & Co.'s ($MRK) Keytruda as the PD-1/PD-L1 market heats up. Release

Suggested Articles

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.